Palomino Laboratories Inc. (PALX)

Palomino Laboratories Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
Selling, General & Admin	3.85	2.7	0.01	0.02
Operating Expenses	4.96	2.7	0.01	0.02
Operating Income	-4.96	-2.7	-0.01	-0.02
Interest & Investment Income	0	0	0	0
Other Non Operating Income (Expenses)	-0.22	-0.46	-0.01	0.01
Pretax Income	-5.18	-3.16	-0.02	-0
Net Income	-5.18	-3.16	-0.02	-0
Net Income to Common	-5.18	-3.16	-0.02	-0
Net Income Growth	-	-	-	-
Shares Outstanding (Basic)	16	7	2	1
Shares Outstanding (Diluted)	16	7	2	1
Shares Change	721.21%	340.48%	147.88%	-
EPS (Basic)	-0.33	-0.47	-0.01	-0.00
EPS (Diluted)	-0.33	-0.47	-0.01	-0.00
EPS Growth	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
EBIT	-4.96	-2.7	-0.01	-0.02

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 10, 2026

Data Sources Report a data error